SCHEMBL3552786

SCHEMBL3552786

CN1CCN(c2cc(C3=C(c4cn(C)c5ccccc45)C(=O)NC3=O)c(F)cc2F)CC1

nearest known ligand 0.60

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
CCNE2 O96020 1/20 0.60
CDK4 P11802 1/20 0.60
CCND1 P24385 1/20 0.60
CCNE1 P24864 1/20 0.60
CDK2 P24941 1/20 0.60
PRKCA P17252 6/20 0.60
GSK3B P49841 6/20 0.60
PRKCB P05771 5/20 0.60
PRKCE Q02156 4/20 0.60
PRKCD Q05655 3/20 0.60
PRKCG P05129 3/20 0.60
PRKCH P24723 2/20 0.59
PRKCQ Q04759 1/20 0.59
PRKCZ Q05513 1/20 0.57
CAMK2B Q13554 1/20 0.57
CAMK2G Q13555 1/20 0.57
CAMK2D Q13557 1/20 0.57
CAMK2A Q9UQM7 1/20 0.57

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3547465 0.85 CDK4 (0.60) CCNE2CDK4CCND1CCNE1CDK2
SCHEMBL4370794 0.85 GSK3B (0.51) CCNE2CDK4CCND1CCNE1CDK2
SCHEMBL3553175 0.81 PRKCH (0.64) CCNE2CDK4CCND1CCNE1CDK2
SCHEMBL7987757 0.81 CCNE2 (0.66) CCNE2CDK4CCND1CCNE1CDK2
SCHEMBL30319849 0.78 CCNE2 (1.00) CCNE2CDK4CCND1CCNE1CDK2
SCHEMBL5686048 0.78 CCNE2 (1.00) CCNE2CDK4CCND1CCNE1CDK2
SCHEMBL4543351 0.76 PRKCB (0.69) CCNE2CDK4CCND1CCNE1CDK2
SCHEMBL4346607 0.76 GSK3B (1.00) CCNE2CDK4CCND1CCNE1CDK2
SCHEMBL4343058 0.76 GSK3B (1.00) CCNE2CDK4CCND1CCNE1CDK2
SCHEMBL990030 0.76 GSK3B (0.62) CCNE2CDK4CCND1CCNE1CDK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1747216-B1 SUBSTITUTED PYRROLE-2, 5-DIONES AS PROTEIN KINASE C INHIBITORS NOVARTIS AG (CH) 2014-01-08 EP claimed
US-7851475-B2 Substituted pyrrole-2, 5-diones as protein kinase C inhibitors NOVARTIS AG (CH) 2010-12-14 US claimed
US-20090221605-A1 SUBSTITUTED PYRROLE-2, 5-DIONES AS PROTEIN KINASE C INHIBITORS NOVARTIS AG (CH) 2009-09-03 US claimed
EP-1747216-A1 SUBSTITUTED PYRROLE-2, 5-DIONES AS PROTEIN KINASE C INHIBITORS Novartis Pharma AG. (CH) 2007-01-31 EP claimed
WO-2005113545-A1 SUBSTITUTED PYRROLE-2, 5-DIONES AS PROTEIN KINASE C INHIBITORS NOVARTIS AG (CH) 2005-12-01 WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090221605-A1 SUBSTITUTED PYRROLE-2, 5-DIONES AS PROTEIN KINASE C INHIBITORS PRKCA, PRKCB, PRKCE CCNE2 602/4885CDK4 193/4885CCND1 582/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.